Winrevair Gains Approval For Pulmonary Arterial Hypertension Patients.
Newly approved Winrevair has shown important benefits to PAH patients. Its high price and correspondingly limited cost-effectiveness could, however, restrain its uptake.
Firstword Pharma World Health Institute For Clinical Drug Administration New England Journal Medicinepublished Phase
Source: forbes.com